Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Racivir vs 3TC in HIV with M184V Mutation
NCT00121979Phase 2Completed
- Sponsor
- Pharmasset Inc.
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of Racivir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Pharmasset Inc. Primary endpoints: Change from baseline in virological response of HIV (log10 HIV-RNA levels) at 2 weeks, Change from baseline in CD4+ count at 2 weeks and 1 more. Started Sep 2004; status: completed.
02
Drugs
Racivir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00121979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121979.